|269.12 -2.19 (-0.81%)||12-08 16:00|
|Targets||6-month :||321.14||1-year :||375.09|
|Resists||First :||274.95||Second :||321.14|
|Supports||First :||266.03||Second :||260.51|
|MAs||MA(5) :||270.63||MA(20) :||268.06|
|MA(100) :||262.54||MA(250) :||249.21|
|MACD||MACD :||0.4||Signal :||-0.1|
|%K %D||K(14,3) :||68.9||D(3) :||71.3|
|52-week||High :||288.45||Low :||211.71|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AMGN ] has closed below upper band by 38.5%. Bollinger Bands are 45.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||272.32 - 273.64||273.64 - 274.94|
|Low:||264.87 - 266.55||266.55 - 268.21|
|Close:||266.02 - 268.67||268.67 - 271.29|
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Wed, 06 Dec 2023
Amgen: Relative Valuation Remains Unattractive - Yahoo Finance
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||535 (M)|
|Shares Float||534 (M)|
|Held by Insiders||0.2 (%)|
|Held by Institutions||79.3 (%)|
|Shares Short||6,770 (K)|
|Shares Short P.Month||6,360 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||14.31|
|Profit Margin||28.2 %|
|Operating Margin||38.9 %|
|Return on Assets (ttm)||7.8 %|
|Return on Equity (ttm)||133.8 %|
|Qtrly Rev. Growth||3.7 %|
|Gross Profit (p.s.)||37.22|
|Sales Per Share||50.13|
|Qtrly Earnings Growth||-19.2 %|
|Operating Cash Flow||10,580 (M)|
|Levered Free Cash Flow||8,900 (M)|
|Price to Book value||18.8|
|Price to Sales||5.36|
|Price to Cash Flow||13.61|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|